Bionoxx is focused on developing immune-modulating therapies, particularly in the realm of oncology. Their primary technologies include oncolytic virotherapy and immune cell therapy, which are designed to target solid tumors. The company is advancing its research pipeline with innovative approaches such as immune-modulating oncolytic viruses and CAR-T cell therapies. Specifically, they are working on a proprietary oncolytic virus known as mOTS-400s, which is aimed at enhancing the efficacy of cancer treatments by harnessing the body's immune response.

In addition to their oncolytic virus research, Bionoxx is also developing CAR-T therapies, which involve engineering a patient's T cells to better recognize and attack cancer cells. This dual approach of combining oncolytic virotherapy with CAR-T technology positions Bionoxx at the forefront of cancer immunotherapy, aiming to improve patient outcomes through targeted and personalized treatment strategies. Their commitment to advancing these technologies reflects a broader trend in the biopharmaceutical industry towards harnessing the immune system to combat cancer more effectively.

South Korea

Bionoxx is a research and development company that develops immune regulation-based anticancer drugs to conquer cancer diseases.

Cancer

Musculoskeletal Diseases

Bionoxx

Systemic Juvenile Idiopathic Arthritis

BNX-E4

Small Molecule Pharmaceuticals

Solid tumor/s

mOTS-412

mWOTS-418

UTTA CAR-T

CAR-T Immunotherapy

Cell Therapies

Biologics

Viral Therapies/Virotherapies

Therapeutic

Bionoxx

Company Details